AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has entered a partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility.   “We are very pleased that Oculis has chosen us to manufacture this treatment,” said Mark Womack, chief business officer, AGC Biologics. “Our Heidelberg site has the experience and expertise to deliver this program from ear...